Old Web
The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes [Abstract]
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI